Reprogramming Metabolic Dysfunction using Nanotechnology: Implications for Obesity and Type 2 Diabetes

Abstract

Obesity and type 2 diabetes (T2D) represent a major globalhealth burden, with increasing prevalence linked to sedentary lifestyles, poor dietary habits, and genetic predisposition. These conditions are strongly interconnected through a range of metabolic dysfunctions, including insulin resistance, chronic inflammation, and dysregulated lipid metabolism. Traditional treatment approaches for obesity and T2D have been limited in their ability to address the underlying causes of metabolic dysfunction. Nanotechnology, however, presents a promising avenue for reprogramming these metabolic disturbances by enabling precise modulation of molecular pathways involved in insulin resistance, adiposity, and glucose homeostasis. Through the development of targeted drug delivery systems, biomolecular modulation, and tissue-specific therapies, nanomedicine offers the potential to reprogram metabolic dysfunction at the molecular level. This review explores the role of nanotechnology in targeting key metabolic processes involved in obesity and T2D, including inflammation, lipid metabolism, and insulin signaling. We also discuss the clinical prospects, challenges, and future directions of nanotechnology-based approaches in reprogramming metabolic dysfunction and improving therapeutic outcomes for patients with obesity-related diabetes. Keywords: Nanotechnology, Metabolic Dysfunction, Obesity, Type 2 Diabetes, Targeted Therapy.